Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has issued an announcement.
ImpediMed Limited has disclosed a change in the securities held by director Ms Christine Emmanuel-Donnelly, reflecting an issuance of 146,408 ordinary shares to IDEAHL Pty Ltd, a trustee entity for the Donnelly Family Trust, in lieu of 15% of her director fees for the quarter ended 31 December 2025, at a deemed price of $0.0355 per share. Following this transaction, Emmanuel-Donnelly’s overall holding, including direct interests and those via the Donnelly Superannuation Fund and IDEAHL Pty Ltd, has increased, underscoring the company’s practice of partially remunerating directors in equity and modestly aligning board compensation with shareholder interests without cash outlay, though the change does not alter control or signal any broader strategic shift.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian-listed medical technology company that develops and commercialises bioimpedance spectroscopy devices used for the non-invasive assessment and monitoring of fluid status in patients, with a focus on conditions such as lymphedema and heart failure across hospital and clinical settings.
Average Trading Volume: 1,179,706
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$71.34M
Learn more about IPD stock on TipRanks’ Stock Analysis page.